Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 274

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 274
---
 and other current assets(866)Total current assets(13,910)Property and equipment, net(6,836)Operating lease right-of-use assets(707)Other assets(64)Total assets$(21,517)Current liabilities:Accounts payable$(852)Accrued liabilities(4,951)Operating lease liabilities, current portion(201)Total current liabilities(6,004)Operating lease liabilities, net of current portion(536)Total liabilities(6,540)Net assets disposed of$(14,977)The Company evaluated various qualitative and quantitative factors related to the disposition of the FYARRO Business and determined the transaction did not meet the criteria for discontinued operations under ASC 205-20, and therefore no reclassification has been made to prior period statements.

15. Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has identified its Chief Executive Officer as the chief operating decision maker and the Company views its operations and manages its business in one operating segment, applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. The CODM assesses performance for the Company's single operating segment and decides how to allocate resources primarily based on research and development expenses incurred, which is a component of the Company's consolidated net income (loss) as reported on the consolidated statement of operations and comprehensive income (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets. Further, segment depreciation expense and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. The Company's revenues relate to sales of FYARRO, which was divested as of March 25, 2025. All the assets and operations of the Company’s sole operating and reportable segment are located in the United States.Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss (in thousands): 

23

Three Months Ended March 31,20252024Product sales, net$7,145 $5,353 Less:FYARRO - research and development expenses5,313 10,271 FYARRO - contract manufacturing expenses— 3,322 ADC assets - contract manufacturing3,475 —